
International Journal of Immunology is a peer-reviewed open access journal that publishes original research articles as well as review articles in all areas of immunology. Immunology is a diverse and growing discipline that can be defined as the study of the tissues, cells and molecules involved in host defense mechanisms. Immunologists attempt to understand how the immune system develops, how the body defends itself against disease, and what happens when it all goes wrong. Priority is given to work that provides fundamental insight into the workings of the immune system. Areas covered include, but are not limited to, innate immunity and inflammation; development; immune receptors, signaling and apoptosis; antigen presentation; gene regulation and recombination; cellular and systemic immunity; vaccines; immune tolerance; autoimmunity and tumor immunology, microbial immunopathology; and transplantation.
The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in biological sciences. This remarkable growth is stimulated by the influx of investigators from other disciplines such as biochemistry, genetics, molecular biology, microbiology, virology and various medical disciplines. These disciplines are so well interlinked with immunology that no immunological challenge can now be properly addressed without sophisticated applications of expertise of combinations of these disciplines. As a consequence, immunology has become a vast and rich field encompassing discoveries and outlooks that range from the highly clinical to the highly molecular. Although such perspectives may appear diverse, they are, in fact, extremely interdependent. The journal seeks to present a balanced overview of contemporary immunology and melds together different aspects of molecular immunology, immunobiology and clinical immunology.
Immunology is the branch of biomedical science that deals with the response of an organism to antigenic challenge and its recognition of what is self and what is not. It deals with the defense mechanisms including all physical, chemical and biological properties of the organism that help it to combat its susceptibility to foreign organisms, material, etc
Immunology has its origins in the study of how the body protects itself against infectious diseases caused by microorganisms, such as bacteria, viruses, protozoa, and fungi, and also parasitic organisms, such as helminth worms. Research / review articles deals with, among other things, the physiological functioning of the immune system in states of both health and disease; malfunctions of the immune system in immunological disorders (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection); the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.
We take great pleasure in welcoming you to our new journal, International Journal of Immunology. We have created this publication with the intention of providing a space for the generation of knowledge, dialogue, critique, debate, and collaboration among an international community of immunologists, pathologists, researchers, scholars, etc.
Our vision is to create a high-quality publication that will be relevant, challenging, thought-provoking, for graduate students, academic researchers and scholars. We welcome original research papers, reviews articles, case studies, book reviews, and works-in progress.
We look forward to welcoming your submissions.
1. Adaptive immunity 11. Cancer and Tumor Immunobiology
2. Immunologic Techniques 12. Cellular & Regional Immunology
3. Transplantation Immunology 13. Combining Cancer Immunotherapies
4. Computational Immunology 14. Allergy prevention and risk factors
5. Immunology 15. Nutritional Immunology
6. Immunotherapy 16. Clinical Immunology
7. Pediatric Immunology 17. Reproductive Immunology
8. Immune Tolerance 18. Fungal Immunology
9. Mucosal Immunology 19. Neuro Immunology
10. Immune Toxicology 20.Immunoinformatics and System
Immune Scientific Networks:
Immunology Leadership & Committees consider proposals for Special Issues Editors will return a decision on your proposal within Two weeks of receipt. To enrich our vision of making the scientific information available at an ease of access, Immunology Leadership & Committees initiated special issue for the open access journals. All the articles published under a special issue focuses on a single topic providing the complete information about the ongoing research providing more insight on an emphasized topic of research enabling the readers access wide forecasted information on a particular topic Issue.
Special Issue Proposals: Special Issue deals with focused research topics of high interest, falling under the scope of the Journal. Special Issues are the pool of articles under a current topic selected from the Ongoing Research under specific discipline. The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in particular areas of research. These articles will provide an opportunity to the readers to understand and access the scientific information.
We encourage potential scientists to organize the Special Issue in their field of interests that fits within the Journal scope. This will provide an opportunity to increase the visibility of the Guest Editors. The Special Issue Titles may be from any basic and clinical area of Science, Technology and Medicine. People interested in publishing a special issue are advised to consider the following guidelines.
Your proposal should contain:
By submitting a Special Issue proposal to Immunology Leadership & Committees, you agree to abide by the Special Issue Editor Protocol should your proposal be accepted
Special issue articles are published immediately upon their acceptance and are released under upcoming regular issues. Special Issues are invited throughout the year. For more information or any queries about the special issues, please write us to specialissues@helicsgroup.net or info@helicsgroup.net
Promoting Your Special Issue
Immunology Leadership & Committees will work with Guest Editors to increase the visibility of the Special Issue in the months leading up to the submission deadline and once it has been published.
What Immunology Leadership & Committees will do:
1. Immunology Leadership & Committees will circulate your Call for Papers to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs. It will also advertise your Call on the Immune websites and other social media platforms. It will re-issue the Call at appropriate intervals.
2. Once the Special Issue is published, announcements will be made to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs as well as on the Immune websites social media platforms.
3. Free access to the Special Issue will be made available in the website to Guest Editors and readers.
What is expected of Guest Editors?
1. We expect that Guest Editors will circulate the Call for Papers within their own personal networks, social media groups, and at any relevant conferences or workshops they may attend.
2. If it has not already been suggested as part of the proposal, consideration should be given to organizing a conference or workshop either to generate submissions or to aid in the development of submitted papers. A symposium or PDW at a well-known conference may also be considered.
3. We expect Guest Editors to identify up to 50 scholars for whom the Special Issue will be particularly relevant
If you have any queries, please contact Elena Griffin (editors.ijit.immune@helicsgroup.net)
Veerendra KoppoluM.ScPh.DC.Cy is a senior scientist in the Department of Biologics Development at AstraZeneca/Medimmune in Gaithersburg, Maryland, USA. Dr. Koppolu is also a honorary faculty member at non-profit organization Novel Global Community Education Foundation (NGCEF) focused in guiding doctoral students. His lectures are highly valued and was awarded Robert H Emmer award and Michael S Gaines awards for this teaching. Dr. Koppolu has published over 50 peer-reviewed papers including research article, review articles, abstracts, book chapters, and books. Dr. Koppolu is serving as reviewer of 30 peer-reviewed international journals including Biotechnology Journal, Journal of Bacteriology, Future microbiology etc. Dr. Koppolu is Editorial advisory board member of International Journal of Applied and Natural Sciences, Editor of Oncology Reports and Reviews, Editor of Holistic Approaches in Oncotherapy, Editor of Open Access Journal of Surgery, Associate Editor of Cancer Therapy and Oncology International Journal, Associate Editor of Research Reviews on healthcare. Dr. Koppolu is a member in international scientific communities such as “American chemical society, American Society of Microbiology, American Association of cancer research, American Society of clinical oncology, and Internationally certified flow cytometry Association. His primary research interests include pre-clinical and clinical development of immunotherapeutic drugs including monoclonal antibodies, bispecifics, and antibody drug conjugates. At AstraZeneca, he helped in the development of drug Durvalumab, an FDA approved drug that prevents tumor immune suppression in urinary bladder cancer. He also worked in the development of immunotherapeutic vaccines for triple negative breast cancer. Dr. Koppolu holds a BS and M.Sc (Biotech) from India, PhD from University of Kansas (USA), and a certification in Flow Cytometry (C.Cy)
Ph.D – Cell, Molecular and Developmental Biology
University of Kansas
M.S – Biotechnology
CSKHPKV University
Pre-clinical and clinical development of monoclonal antibodies and novel small molecules as breakthrough therapies for cancer and infectious diseases. Characterization and Potency evaluation of drugs and vaccines.
Veerendra Koppolu, Ichie Osaka, Jeff M. Skredenske, Bria Kettle, Scott Hefty and Susan M. Egan “Small molecule inhibitor of Shigella flexneri master virulence regulator, VirF”. Infect Immun. 2013 Nov;81(11):4220-31. PMID: 24002059
Jeff M. Skredenske, Veerendra Koppolu, Ana Kolin, James Deng, Bria Kettle, Byron Taylor and Susan M. Egan “Identification of a small molecule inhibitor of bacterial AraC family activators”. J Biomol Screen. 2013 Jun;18(5):588-98. (PMID: 23364515)
Veerendra Koppoluand Susan M. Egan “Small molecule inhibitor of Shigella flexneri master virulence regulator, VirF”. 7th Asia-Pacific Biotech Congress 2015, China. Abstract
Veerendra Koppolu and Veneela KR Vasigala. "Role of Escherichia coli in Biofuel Production." Microbiology Insights 9 (2016): 29.
Veerendra Koppolu, Veneela KR Vasigala (2016)CTLA-4 Antibodies in Cancer Immunotherapy. MOJ Immunol 3(3): 00092. DOI: 10.15406/moji.2016.03.00092
Veerendra Koppolu, Veneela KR Vasigala(2016) Nivolumab in the treatment of Metastatic Melanoma. (Accepted, Journal of Cancer Research and Therapeutics)
SriHari Raju Mulagapati, Veerendra Koppolu, Raju T Shantha (2017) Decoding of O-linked Glycosylation by Mass Spectrometry. Biochemistry, 2017, 56 (9), pp 1218–1226
Veerendra Koppolu, Veneela KR Vasigala(2017)Cancer Immunotherapy Arsenal: Current and Promising New Approaches. Cancer Therapy and Oncology International Journal. Volume 5 Issue 3 - May 2017